Trial Profile
A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension [EXTENSION OF 700243262]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Jun 2021
Price :
$35
*
At a glance
- Drugs Bosentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions; Registrational
- Acronyms FUTURE 3 Ext
- Sponsors Actelion Pharmaceuticals
- 07 Jul 2020 Status changed from active, no longer recruiting to completed.
- 06 Feb 2020 Planned End Date changed from 1 Sep 2014 to 31 May 2020.
- 06 Feb 2020 Status changed from completed to active, no longer recruiting.